In-vivo T-cell depletion with pretransplant anti-thymocyte globulin (ATG) reduces GvHD without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors

被引：0
|
作者：
Kröger, N
Zabelina, T
Krüger, W
Renges, H
Rischewski, J
Ayukatan, F
Tögel, F
Sonnenberg, S
Fiegel, H
Erttmann, R
Schade, U
Zander, A
机构：
来源：
BONE MARROW TRANSPLANTATION | 2002年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O253
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [1] In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors
    Kröger, N
    Zabelina, T
    Krüger, W
    Renges, H
    Stute, N
    Rischewski, J
    Sonnenberg, S
    Ayuk, F
    Tögel, F
    Schade, U
    Fiegel, H
    Erttmann, R
    Löliger, C
    Zander, AR
    [J]. BONE MARROW TRANSPLANTATION, 2002, 29 (08) : 683 - 689
  • [2] In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors
    N Kröger
    T Zabelina
    W Krüger
    H Renges
    N Stute
    J Rischewski
    S Sonnenberg
    F Ayuk
    F Tögel
    U Schade
    H Fiegel
    R Erttmann
    C Löliger
    AR Zander
    [J]. Bone Marrow Transplantation, 2002, 29 : 683 - 689
  • [3] Comparison of conditioning with or without anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation from related donors in patients with good risk myeloid leukemia.
    Kröger, N
    Zabelina, T
    Kroger, W
    Renges, H
    Sonnenberg, S
    Togel, F
    Fiegel, H
    Rischewski, J
    Ayukatan, F
    Zander, A
    [J]. BLOOD, 2001, 98 (11) : 418A - 418A
  • [4] The Efficacy of Anti-Thymocyte Globulin for in Vivo T Cell Depletion in Conditioning in Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation From Related and Unrelated Donors
    Chadievski, Lazar
    Veljanovska, Aleksandra Pivkova
    Stojanovska, Simona
    Cvetanovski, Milche
    Ridova, Nevenka
    Kocoski, Bozidar
    Trajkova, Sanja
    Labachevska, Marija Popova
    Chevreska, Lidija
    Georgievski, Borche
    Stavridis, Panovska
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S290 - S290
  • [5] Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) As Gvhd Prophylaxis Is Effective in Haploidentical Peripheral Stem Cell Transplantation and without Increasing Risk of Relapse
    Lin, Ching Chan
    Chen, Tzu Ting
    Lo, Wen Jyi
    Lein, Ming Yu
    Hiseh, Ching Yun
    Lin, Chen Yuan
    Bai, Li-Yuan
    Chiu, Chang-Fang
    Lin, Che Hung
    Yeh, Su-Peng
    [J]. BLOOD, 2017, 130
  • [6] Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin
    Kröger, N
    Zabelina, T
    Krüger, W
    Renges, H
    Stute, N
    Schrum, J
    Kabisch, H
    Schafhausen, P
    Jaburg, N
    Löliger, C
    Schäfer, P
    Hinke, A
    Zander, AR
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 1060 - 1071
  • [7] In-Vivo T-Cell Depletion with Rabbit Anti-Thymocyte Globulin (r-ATG) Prevents Severe Acute and Chronic Graft Versus Host Disease (GVHD) and Allows Safe Allogeneic Stem Cell Transplantation (allo-SCT) From Mismatched, Unrelated Donors
    Slack, James L.
    Leis, Jose F.
    Reeder, Craig B.
    Mikhael, Joseph R.
    Noel, Pierre
    Mesa, Ruben A.
    Tibes, Raoul
    Betcher, Jeffrey A.
    Peterson, Mary E.
    Higgins, Meagan S.
    Gillette-Kent, Ginger
    Tremblay, Lisa D.
    Olson, Jane J.
    Adams, Roberta H.
    [J]. BLOOD, 2011, 118 (21) : 862 - 863
  • [8] Clinical impact of different anti-thymocyte globulin doses as GVHD prophylaxis in patients receiving stem cell transplantation from unrelated donors
    Busca, A.
    Giaccone, L.
    Dellacasa, C. M.
    Aydin, S.
    Brunello, L.
    Festuccia, M.
    Iovino, G.
    Butera, S.
    Maffini, E.
    Ciochetto, C.
    Nicolino, B.
    Nicolosi, M.
    Santambrogio, E.
    Montefusco, M.
    Manetta, S.
    Fornaro, M. J.
    Bruno, B.
    [J]. BONE MARROW TRANSPLANTATION, 2017, 52 : S205 - S205
  • [9] T-cell depletion with anti-thymocyte globulin (ATG) favours superior overall survival and lowers rates of relapse and GVHD when compared to alemtuzumab in patients undergoing allogeneic haematopoietic stem cell transplantation for myelofibrosis: A retrospective single centre analysis
    Alimam, S.
    Beauverd, Y.
    McLornan, D.
    Ibrahim, M.
    Saha, C.
    Raj, K.
    de Lavallade, H.
    Kenyon, M.
    Harrison, C. N.
    Pagliuca, A.
    Mufti, G. J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 16 - 16
  • [10] Anti-thymocyte globulin(ATG) could improve the outcome of allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory peripheral T-cell lymphoma
    Jun, Y.
    Chun, W.
    [J]. BONE MARROW TRANSPLANTATION, 2015, 50 : 5624 - 5624
12345